2025-523676-23-00Not yet recruitingPhase 4
The effect of early Landiolol in patients with ST-elevation acute coronary syndrome undergoing primary percutaneous coronary intervention – A prospective, randomized, double-blinded, placebo-controlled, phase IV pilot trial (STEMILAND-1)
The effect of early Landiolol in patients with ST-elevation acute coronary syndrome undergoing primary percutaneous coronary intervention – A prospective, randomized, double- blinded, placebo controlled, phase IV pilot trial (STEMILAND-1)
Source: EU CTIS (euclinicaltrials.eu) · Last updated 16 Sept 2026
Brief summary (registry, in English)
The primary objective is to evaluate the feasibility of very early continuous i.v. administration of the highly cardioselective betablocker Landiolol in anterior/lateral ST-elevation acute coronary syndrome (STE-ACS).
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 5 Sept 2025
- Start date
- 7 Jan 2026
- Lead sponsor
- Medical University Of Vienna
- Diseases
- Coronary artery disease
- EU CT number
- 2025-523676-23-00
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 60
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a heart attack of the front or side wall of the heart (ST-elevation acute coronary syndrome) who are treated at the study center. They must be stable and have a heart rate above 70 per minute.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Anterior or lateral ST-elevation acute coronary syndrome, with ST-segment elevation in two or more of the chest leads V1-V6, and I and aVL. Hemodynamically stable (MAP >60 mmHg, heart rate > 70/min).
Main reasons for not taking part
- Known or suspected pregnancy
- Acute asthma exacerbation
- Acute heart failure or cardiogenic shock (Killip Classes III and IV)
- Known problems of the heart's electrical conduction system (e.g., sick-sinus-syndrome, AV-block II° or III°)
- Allergy or insensitivity to ß-blockers
Read by machine on 9 Nov 2026.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Other illness
- Known pathologies of the cardiac electrical conduction system (e.g., sick-sinus-syndrome, AV-block II° or III°)
- Acute heart failure and cardiogenic Shock (Killip Classes III and IV)
- Allergy or insensitivity to ß-blockers
- Known pulmonary hypertension
- Heart rate < 50 bpm
Other
- Known or suspected pregnancy
- Acute asthma exacerbation
- Severe metabolic acidosis
- Known pheochromocytoma
- Anticipated time to wire-crossing >120 minutes after first medical contact
- Thrombolysis candidate as defined by treating physician
Who the study is looking for
- Anterior or lateral ST-elevation acute coronary syndrome (STE-ACS; defined as ST-segment elevation in two or more of precordial leads V1-V6, and I and aVL, representing anterior wall infarction or ischemia)
- Treated at our study center
- Age >= 18 years
- Hemodynamically stable (MAP >60 mmHg, heart rate > 70/min)
- Oral and written informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Klinik Landstrasse | Vienna | Austria | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.